Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14SVV | ISIN: FR0012596468 | Ticker-Symbol: RFM
Frankfurt
20.11.24
08:24 Uhr
0,650 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SENSORION SA Chart 1 Jahr
5-Tage-Chart
SENSORION SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,6600,66816:12

Aktuelle News zur SENSORION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.11.Sensorion Announces Its Participation in Upcoming Investor Conferences to be Held in November 2024142Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
17.10.Sensorion Announces its Participation in the 31st Annual Congress of the European Society of Gene and Cell Therapy and the Presentation of Several Posters on GJB2-GT188Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
SENSORION Aktie jetzt für 0€ handeln
26.09.Sensorion Announces Webconference for Retail Shareholders on October 10, 2024246Sensorion to host a webconference dedicated to its retail shareholders on October 10, 2024, in French, at 6pm CET (12pm ET) Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering...
► Artikel lesen
24.09.Sensorion GAAP EPS of -€0.05, revenue of €3.33M2
23.09.Sensorion Reports New Positive Clinical Results Presented at the World Congress of Audiology329Sensorion reported positive initial safety data on the First Patient Injected in Audiogene, its Phase 1/2 gene therapy clinical trial of SENS-501 Sensorion announced positive final results...
► Artikel lesen
23.09.Sensorion Announces the Availability of its Half Year 2024 Report199Regulatory News: Sensorion (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within...
► Artikel lesen
20.09.Sensorion Announces New Positive Clinical Data Across its Gene Therapy and Small Molecule Programs at the World Congress of Audiology in Paris251Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
18.09.Sensorion Reports 2024 First Half Results and Highlights Recent Updates318First patient treated in SENS-501 Audiogene clinical study; well on-track for first cohort recruitment completion by year-end 2024 Final data to be presented from the Phase 2a study of...
► Artikel lesen
12.09.Sensorion Announces Its Participation in the 59th Annual Inner Ear Biology Workshop223Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
02.09.Sensorion Announces its Participation in the World Congress of Audiology in September 2024 in Paris and will Lead a Symposium on Medical Advances in the Field of Hearing Loss287Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
05.08.Sensorion Announces its Participation in Stifel's Biotech Summer Summit327Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
23.07.Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity378Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
15.07.Sensorion Announces New Positive Secondary Efficacy Endpoints Data From SENS-401 Phase 2a Clinical Trial For The Preservation Of Residual Hearing Loss290Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
27.06.Sensorion Announces the Appointment of Laurene Danon as Chief Financial Officer283Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
20.06.Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies285Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
30.05.Sensorion Publishes Results of Combined Shareholders' General Meeting Resolutions253Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
28.05.Sensorion Announces its Participation in Upcoming Investor Conferences in June 2024302Regulatory News: Sensorion (FR0012596468 ALSEN) (Paris:ALSEN)a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent...
► Artikel lesen
07.05.Sensorion Provides Preliminary Documents for the Combined Shareholders' General Meeting of May 29, 2024290Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
26.04.Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting473Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
10.04.Sensorion Announces its Participation in the Van Lanschot Kempen's Life Sciences Conference442Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within...
► Artikel lesen
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1